A Study of HGS1029 in Subjects With Relapsed or Refractory Lymphoid Malignancies
The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.
Lymphoid Malignancies
DRUG: HGS1029
Type, frequency and severity of adverse events, 1 year
Measure pharmacokinetic profile, 1st two months of the study|Evaluation of pharmacodynamics, 1st two months of the study|Evaluation of possible anti-tumor activity, Every 2 months while on study
The purpose of this study is to determine if HGS1029 is safe and well tolerated in patients with relapsed or refractory lymphoid malignancies.